NO962717L - Diaryl-5,6-kondenserte, heterosykliske syrer som leukotrienantagonister - Google Patents

Diaryl-5,6-kondenserte, heterosykliske syrer som leukotrienantagonister

Info

Publication number
NO962717L
NO962717L NO962717A NO962717A NO962717L NO 962717 L NO962717 L NO 962717L NO 962717 A NO962717 A NO 962717A NO 962717 A NO962717 A NO 962717A NO 962717 L NO962717 L NO 962717L
Authority
NO
Norway
Prior art keywords
diaryl
fused heterocyclic
leukotriene antagonists
heterocyclic acids
compounds
Prior art date
Application number
NO962717A
Other languages
English (en)
Other versions
NO962717D0 (no
Inventor
Robert N Young
Marc Labelle
Yves Leblanc
Cheuk K Lau
Claude Dufresne
Yves Gareau
Yi Bin Xiang
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO962717L publication Critical patent/NO962717L/no
Publication of NO962717D0 publication Critical patent/NO962717D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel (I) ^ ¿tøm-ZWRV* R5 (I) er antagonister av virkningene av leukotriener. Disse forbindelser er anvendbare som antiastmatiske midler, antiallergiske midler, antiinflammator iske og cytobeskyttende midler. De er også anvendbare ved behandling av an- gina, cerebrale spasmer, glomerulær nefritt, hepatitt, endotoksemi, uveitt og transplantatavstøtning.
NO962717A 1993-12-28 1996-06-27 Diaryl-5,6-kondenserte, heterosykliske syrer som leukotrienantagonister NO962717D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17493793A 1993-12-28 1993-12-28
US08/260,592 US5472964A (en) 1992-12-22 1994-06-16 Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
PCT/CA1994/000716 WO1995018132A1 (en) 1993-12-28 1994-12-22 Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists

Publications (2)

Publication Number Publication Date
NO962717L true NO962717L (no) 1996-06-27
NO962717D0 NO962717D0 (no) 1996-06-27

Family

ID=26870689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962717A NO962717D0 (no) 1993-12-28 1996-06-27 Diaryl-5,6-kondenserte, heterosykliske syrer som leukotrienantagonister

Country Status (12)

Country Link
US (1) US5472964A (no)
EP (1) EP0737196A1 (no)
JP (1) JP3594603B2 (no)
CN (1) CN1148389A (no)
AU (1) AU684884B2 (no)
CA (1) CA2180014A1 (no)
CZ (1) CZ187996A3 (no)
FI (1) FI962639L (no)
HU (1) HUT76544A (no)
NO (1) NO962717D0 (no)
SK (1) SK83896A3 (no)
WO (1) WO1995018132A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
SK105698A3 (en) * 1996-02-08 1999-05-07 Merck & Co Inc Method of treatment and pharmaceutical composion
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1321169A1 (en) * 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
WO2006017505A2 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
MX2007004976A (es) 2004-10-25 2007-06-14 Schering Corp Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
EP2004609A2 (en) * 2006-03-06 2008-12-24 Farmaprojects, S.A. Process for preparing a leukotriene antagonist
WO2008008327A2 (en) * 2006-07-11 2008-01-17 Schering Corporation Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
PT2268646E (pt) * 2008-04-11 2013-12-10 Janssen Pharmaceutica Nv Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4
US9532717B2 (en) * 2008-10-28 2017-01-03 The Procter & Gamble Company Method for diagnosing vulvovaginal disorders
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
CN110386888A (zh) * 2019-07-30 2019-10-29 上海红蓝医药科技有限公司 一种低成本、高收率的1-(巯甲基)环丙基乙酸生产工艺
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
CA1322005C (en) * 1987-11-25 1993-09-07 Robert N. Young Benzoheterazoles
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
HU222344B1 (hu) * 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
US5308850A (en) * 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5506227A (en) * 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists

Also Published As

Publication number Publication date
EP0737196A1 (en) 1996-10-16
AU684884B2 (en) 1998-01-08
JP3594603B2 (ja) 2004-12-02
WO1995018132A1 (en) 1995-07-06
FI962639A7 (fi) 1996-06-26
US5472964A (en) 1995-12-05
HUT76544A (en) 1997-09-29
FI962639A0 (fi) 1996-06-26
CN1148389A (zh) 1997-04-23
SK83896A3 (en) 1997-02-05
AU1378195A (en) 1995-07-17
CZ187996A3 (en) 1997-01-15
HU9601772D0 (en) 1996-09-30
JPH09507080A (ja) 1997-07-15
NO962717D0 (no) 1996-06-27
FI962639L (fi) 1996-06-26
CA2180014A1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
FI914796A0 (fi) Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI944734A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
NO920681L (no) Kinolinholdige ketosyrer som leukotrien-antagonister
NO952495L (no) Diaryl-5,6-kondenserte heterosykliske syrer som leukotrienantagonister
AU639612B2 (en) Hydroxyalkylquinoline ether acids as leukotriene antagonists
WO1995004741A1 (en) Aza-5,5-fused heterocyclic acids as leukotriene antagonists
ATE317224T1 (de) Chinolin-leukotrien-antagonisten
MY107767A (en) Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists